Cabaletta Bio Inc (CABA) Stock Price, Quote & News

Company Profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythe...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 759 3100

Website: www.cabalettabio.com

Address:

2929 Arch Street, Suite 600, Philadelphia, United States

Achandler787 Jan. 13 at 10:29 PM

$CABA $BTC.X $NKE

0 · Reply

Moonman321 Jan. 13 at 9:27 PM

$CABA $NVDA $VRTX $CABA 🚀 Wall Street is STACKING on Cabaletta Bio! 🚀 The gap between the current price and analyst expectations is becoming impossible to ignore. We are looking at potential 1,000%+ upside if these top-tier targets hit. The "High Analyst" Leaderboard 🏆 * Cantor Fitzgerald (Josh Schimmer): $30.00 – $50.00 🎯 * The Bull Case: Most aggressive target on the Street. Betting big on the "preconditioning-free" CAR-T approach. If they de-risk lupus/myositis without chemo, this is a moonshot. * Wells Fargo (Derek Archila): $35.00 🎯 * The Bull Case: High conviction on the RESET™ platform’s scalability across multiple autoimmune indications. * Stifel Nicolaus: $32.00 🎯 * The Bull Case: Eyes on the 2026 clinical data readouts as the ultimate "proof of concept" catalyst. * H.C. Wainwright (Douglas Tsao): $30.00 🎯 * The Bull Case: Focuses on manufacturing efficiency and FDA de-risking of their automated platform. * Jefferies (Roger Song): $36.00 Currently 2.15 lol

0 · Reply

MiroslavBroz Jan. 13 at 8:17 PM

$CABA

1 · Reply

01xxxxx Jan. 13 at 8:07 PM

$CABA I don’t understand how a company who has such a great pipe line trade at such a low price. How many people in the world suffer from auto immune disease

1 · Reply

KNCourt24 Jan. 13 at 4:56 PM

$CHR $CABA $ATCH $PAVS keep CHR on watch nasdaq hearing update due AH today/early PM tomorrow + BO news update still pending

0 · Reply

KNCourt24 Jan. 13 at 3:33 PM

$CABA it’s consolidating for next big move over $5+

0 · Reply

DragonAlgo Jan. 13 at 3:25 PM

🐉 $CABA CALL — DragonAlgo® Signal Contract: CABA CALL Expiry: 2026-02-20 | Strike: $7.50 | Type: CALL Option Plan (premium): Entry: $0.10 Stop: $0.07 TP1: $0.13 TP2: $0.17 TP3: $0.24 🔗 https://dragonalgo.com

0 · Reply

The1Ski Jan. 13 at 3:21 PM

$CABA Wish I knew what news is needed for this to go up

1 · Reply

MoneyGroupLLC Jan. 13 at 1:52 AM

Enter: $CABA Calls Strike Price: $2 Expiry Date: FEB 20 2026 Buy in Price: $0.13 - $0.15 Sell Price: $0.27 Profit : +110% (Turn every $1 into $2.10) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

GfromTn Jan. 12 at 10:12 PM

$CABA atara got slapped today the only one in the ring this far along is CABA welcome to the team if you were investing in atara and need to continue… also my ixhl friends that means apnimed and ixhl are only sleep apnea pill producers on the market right now

0 · Reply

Cabaletta Bio Announces 2026 Strategic Priorities

Jan 12, 2026, 7:30 AM EST - 1 day ago

IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms

Dec 3, 2025, 5:23 PM EST - 5 weeks ago

Cabaletta Bio, Inc. (CABA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 7:30 AM EST - 2 months ago

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 8:00 AM EST - 2 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December

Oct 27, 2025, 7:00 AM EDT - 2 months ago

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

Oct 14, 2025, 8:00 AM EDT - 3 months ago

Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant

Oct 9, 2025, 12:00 PM EDT - 3 months ago

Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

Oct 7, 2025, 6:20 AM EDT - 3 months ago

Cabaletta Bio: Still Optimistic, With News Being Guided To Be Shared Soon

Aug 27, 2025, 8:00 AM EDT - 4 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Aug 7, 2025, 7:30 AM EDT - 5 months ago

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 11:07 AM EDT - 5 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT NGNE NTLA QURE RCKT

Jun 11, 2025, 9:54 AM EDT - 7 months ago

Cabaletta Bio Announces Pricing of Public Offering of Securities

Jun 11, 2025, 9:49 AM EDT - 7 months ago

Cabaletta Bio: Sector Headwinds And Funding Issues

Jun 11, 2025, 6:15 AM EDT - 7 months ago

Cabaletta Bio Announces Proposed Public Offering of Securities

Jun 11, 2025, 6:00 AM EDT - 7 months ago

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

May 29, 2025, 8:00 AM EDT - 8 months ago

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

May 15, 2025, 7:00 AM EDT - 8 months ago

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

Mar 31, 2025, 7:00 AM EDT - 10 months ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 7:00 AM EDT - 10 months ago

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Feb 26, 2025, 8:00 AM EST - 11 months ago

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 10:21 AM EST - 11 months ago

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 18, 2025, 7:00 AM EST - 11 months ago

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 11, 2025, 8:00 AM EST - 1 year ago

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Jan 29, 2025, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Jan 6, 2025, 2:28 PM EST - 1 year ago

Cabaletta Bio: Finding Optimism In Dire Straits

Oct 22, 2024, 11:41 AM EDT - 1 year ago

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Sep 25, 2024, 4:30 PM EDT - 1 year ago

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Jun 28, 2024, 1:42 PM EDT - 1 year ago

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Jun 14, 2024, 2:00 AM EDT - 1 year ago

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

May 15, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Mar 21, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

Feb 1, 2024, 4:30 PM EST - 2 years ago

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Jan 31, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 2:53 AM EST - 2 years ago

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Jan 2, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 5:58 AM EST - 2 years ago

Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology

Dec 10, 2023, 2:44 AM EST - 2 years ago

Buy Cabaletta Bio's Promising SLE Treatment

Nov 28, 2023, 4:30 PM EST - 2 years ago

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 3:55 PM EST - 2 years ago

Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy

Nov 9, 2023, 7:00 AM EST - 2 years ago

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 8:15 AM EST - 2 years ago

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

Sep 19, 2023, 4:56 AM EDT - 2 years ago

Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Achandler787 Jan. 13 at 10:29 PM

$CABA $BTC.X $NKE

0 · Reply

Moonman321 Jan. 13 at 9:27 PM

0 · Reply

MiroslavBroz Jan. 13 at 8:17 PM

$CABA

1 · Reply

01xxxxx Jan. 13 at 8:07 PM

$CABA I don’t understand how a company who has such a great pipe line trade at such a low price. How many people in the world suffer from auto immune disease

1 · Reply

KNCourt24 Jan. 13 at 4:56 PM

$CHR $CABA $ATCH $PAVS keep CHR on watch nasdaq hearing update due AH today/early PM tomorrow + BO news update still pending

0 · Reply

KNCourt24 Jan. 13 at 3:33 PM

$CABA it’s consolidating for next big move over $5+

0 · Reply

DragonAlgo Jan. 13 at 3:25 PM

0 · Reply

The1Ski Jan. 13 at 3:21 PM

$CABA Wish I knew what news is needed for this to go up

1 · Reply

MoneyGroupLLC Jan. 13 at 1:52 AM

0 · Reply

GfromTn Jan. 12 at 10:12 PM

0 · Reply

TheRealShortSqueezy Jan. 12 at 8:40 PM

$HYFT: Cup & Handle Breakout in Play 🚨‼️ MindWalk Holdings Corp is forming a classic cup and handle pattern, a bullish setup that often signals trend continuation. After an extended consolidation, price has reclaimed key resistance in the $2.50–$2.65 zone, suggesting renewed strength. Technical highlights: 📈Clear cup and handle formation on the daily chart 📈Breakout above prior resistance with solid follow-through 📈Higher-low structure signaling improving demand 📈Measured move upside targets near $3.60 → $4.40 → $4.90 Adding to the setup, MindWalk announced a share repurchase program on Oct 9, 2025, a shareholder-friendly catalyst that could help tighten supply as price approaches higher levels. If volume continues to support the move, HYFT may be entering a new bullish leg, with momentum traders watching closely as the pattern develops. Communicated Disclaimer: https://bit.ly/45yIR8a Sector Peers: $CRSP $IGMS $ANTX $CABA

1 · Reply

Moonman321 Jan. 12 at 7:43 PM

$CABA $VRTX $NVDA 6M / 1D chart is doing exactly what strong bases do after a spike: big run → long digestion → tight coil near the pivot. We had the explosive move from the ~$1.20–$1.30 area up to ~$3.67. Since then, it’s been months of boring, frustrating consolidation — exactly how weak hands exit and strong hands accumulate. The key level is $2.00–$2.10 (especially ~$2.08). Price keeps coming back to this zone and refuses to break down. Recent dips below were classic shakeouts, not trend breaks. Structure-wise, this is higher lows compressing into a tight range. Volatility has been bleeding off. That’s not bearish — that’s pressure building. Levels to watch: Support: $2.00–$2.08 Resistance: $2.35–$2.50 → $2.60–$2.75 → $3.00 Prior high: ~$3.67 If $2.08 holds and we reclaim $2.35–$2.50 with volume, the path opens quickly. This setup mirrors the kind of base that precedes a larger step-up move.

0 · Reply

CattleFarmerJ Jan. 12 at 6:57 PM

$CABA Hopefully we get news in end of February/March later the better for Q1 news and if it is positive and continued proof of a cure to the autoimmune diseases. With 1H full report to follow being even more evidence. We see then will be in the area of serious acquisition zone for major companies like LLY, JNJ, NOVO etc. If it get to this point could easily see a 5b-8b price. So for all the people like me in this for the last 2 years dont sell to quick and remember it could be 2 months till the first news with is grwat news. When its bad news they release it sooner to try to have more time to plan.

0 · Reply

TheRealShortSqueezy Jan. 12 at 6:05 PM

$HYFT : Positioned in an $8B+ Global Vaccine Opportunity 💰 MindWalk Holdings Corp. delivered strong growth in its latest quarterly earnings, reinforcing confidence in its Bio-Native AI strategy and adding fuel to growing momentum in the stock. Latest earnings highlights: 🔹 Revenue up 54% YoY to $4.1M, a record quarterly result 🔹 Gross profit up 94%, with margins expanding to ~65% 🔹 Operating loss narrowed, reflecting improving efficiency 🔹 ~$16.5M in cash, supporting continued program advancement These results point to rising demand for MindWalk’s HYFT Deep Data and LensAI platform, alongside disciplined, capital-efficient execution. Backed by recent scientific breakthroughs, $HYFT is gaining visibility and momentum as platform validation continues to resonate with the market. Execution is strengthening, momentum is building, and the setup ahead looks compelling. 📈 Communicated Disclaimer: https://bit.ly/45yIR8a Sector Peers: $CRSP $ABCL $CABA $ENTX

0 · Reply

Moonman321 Jan. 12 at 4:26 PM

$CABA $VRTX $NVDA 🚨 $CABA | This is the part most people miss. The last major run (2022–2023) didn’t start on news. It started after months of boredom, tight ranges, and nonstop doubt. Volume dried up. Sentiment broke. People gave up. Then rates shifted, biotech woke up, and the stock exploded. That setup is back. Same tight basing. Same shallow pullbacks. Same “nothing’s happening” crowd. Same disbelief phase that always shows up right before the move. What’s better this time: • A more mature pipeline • Larger, validated autoimmune markets • Institutions quietly re-engaging on the science Now layer in the macro: • Rate cuts coming • Capital rotating out of mega-caps • Small-cap biotech historically rips early in easing cycles No fireworks yet? Perfect. That’s exactly how it looked last time too. Same ingredients. Same disbelief. Same setup. History doesn’t repeat — but this one is rhyming loud.

2 · Reply

Bronco6970 Jan. 12 at 4:24 PM

$CABA if we break and hold above $2.30 this week, which is not asking for much, it will be an extremely bullish technical sign that we are off to the races. 💪👊🏻🔥

0 · Reply

Moonman321 Jan. 12 at 4:17 PM

$CABA $NVDA $CABA | Context matters: Gwen Binder presenting this week at a major biotech investor/partnering conference isn’t about hype — it’s about institutional eyes back on the science. That’s how these moves start. Quiet diligence, models refreshed, positioning before anyone tweets about it. Add in the macro: rate cuts coming, capital rotating back into small-cap biotech, and suddenly setups like this start to matter again. We’ve seen this movie before. Late 2022–early 2023 wasn’t driven by flashy PR — it was driven by rates + basing + improving sentiment, then the stock ran. Same ingredients showing up again. No need for noise. Patience wins.

0 · Reply

Achandler787 Jan. 12 at 2:27 PM

$CABA their scientific officer Gwen Binder presenting this week at a bio conference that attracts major investors - GREAT NEWS!

0 · Reply

TheRealShortSqueezy Jan. 12 at 2:21 PM

📌 $HYFT : Weekly Chart Setting Up for Expansion MindWalk holdings is pressing into key weekly resistance near $3.25, aligning with the cup level on the weekly timeframe and signaling growing upside potential. 🔍 Weekly structure highlights: 🔹 Price is firmly challenging the $3.25 weekly cup level 🔹 Strong recovery from long term lows with clear higher-low structure 🔹 Momentum accelerating as price moves through the base 🎯 Upside levels in focus as momentum builds: 📈 $3.65 📈 $4.00 📈 $4.40 📈 $4.90 📈 $5.43 📈 $5.90–$6.50 zone A sustained push through $3.25 on the weekly sets the stage for a broader move higher, with the chart offering clear expansion potential into upper resistance bands. Positive market reaction to recent breakthroughs reinforces HYFT’s positioning as a potential platform winner in the multi billion dollar influenza vaccine market. Communicated Disclaimer: https://bit.ly/45yIR8a Sector Peers: $IGMS $ANTX $CABA $ENTX

0 · Reply

Achandler787 Jan. 12 at 2:20 PM

$CABA this innovative manufacturing process is what they emphasized on the call with CITI - it’s scalable, on demand and specific to the patient with no issues of supply and inexpensive= huge for manufacturing at scale without big investment. They can go all the way to efficient massively profitable product themselves! Or be bought out for Big $ -

1 · Reply

Bronco6970 Jan. 12 at 1:34 PM

$CABA Regulatory interactions — especially around trial design, endpoints, or accelerated pathways — are huge catalysts in biotech: Formal feedback from FDA on registrational trial designs and requirements can significantly reduce uncertainty. Any Fast Track / Breakthrough Therapy designation expansions or special advice will boost sentiment and valuation.

0 · Reply

Bronco6970 Jan. 12 at 1:31 PM

$CABA Here are the most likely next big catalysts that could meaningfully move Cabaletta Bio. Cabaletta’s lead program is rese-cel (resecabtagene autoleucel), a CAR-T therapy targeting autoimmune diseases. Recent positive data showed strong clinical responses (e.g., remission and improvement without immunosuppressants), which has historically caused stock pops. Upcoming full Phase 1/2 data readouts or expanded cohort results — particularly for myositis, lupus (SLE), systemic sclerosis (SSc), and myasthenia gravis (gMG) — could be major catalysts. 💪

0 · Reply

Market Cap	212.75M
Revenue (ttm)	0.00
Net Income (ttm)	-115.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,405,900
Avg Vol	3,245,560
Day's Range	N/A - N/A
Shares Out	96.27M
Stochastic %K	55%
Beta	3.25
Analysts	Strong Sell
Price Target	$13.12